Forest Namenda Has 10% Off-Label Use Based On Initial Launch Data

The company said 70% of use was in moderate Alzehimer's cases and 20% was in severe cases. The company expects to file an sNDA for a mild-to-moderate indication by "late this summer."

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet